In the long-term survival of patients with systemic lupus erythematosus (SLE), cardiovascular disease (CVD) is a leading cause of death. Recently, multimodality cardiovascular imaging methods have been adopted for the evaluation of cardiovascular risk, which has shown to be associated with both traditional cardiovascular risk factors and SLE-specific conditions. Quantitative imaging biomarkers, which can describe both morphological and functional abnormalities in the heart, are expected to provide new insights to stratify cardiovascular risks and to guide SLE management by assessing individual responses to therapies either protecting the cardiovascular system or suppressing the autoimmune reactions. In this review, we will discuss cutting-edge cardiovascular imaging techniques and potential clinical applications and limitations of those techniques for the evaluation of major SLE-related heart disorders. Lupus (2015) 24, 1126-1134.
Introduction
Systemic lupus erythematosus (SLE) is a complex autoimmune disease with multiple target-organ involvement. Owing to improved and evolving clinical practice patterns over the last few decades, the leading cause of death affiliated with SLE has changed significantly. 1 Today, cardiovascular disease (CVD) has become a main killer of SLE patients. 2, 3 Compared to the general population, patients with SLE have a high risk of cardiovascular disease. Coronary artery disease (CAD), myocarditis, endocarditis-valvular disease and pericarditis are major manifestations of cardiac involvement in SLE patients. The accelerated progression of heart damage is thought to be promoted by both traditional cardiovascular risk factors and SLE-specific conditions. Multiple SLE-specific mechanisms, such as autoimmune responses, altered autoantibody and cytokine levels, and lipid dysfunctions, can accelerate the progression of overall atherosclerotic burden. 4 Co-existing target-organ involvement, such as lupus nephritis (LN), may accelerate the progression of CVDs. In addition, routine immunosuppressive treatments targeting SLE flares and activities, such as high-dose glucocorticoid pulse therapy, can further contribute to heart damage and increase risk for CVDs. 5 Therefore, early detection and quantification of pathological changes are important for assessing the benefits of cardiovascular prevention in SLE management.
Taking advantage of rapid technical development in the past decade, cardiovascular imaging has become a powerful tool for the quantitative assessment of cardiovascular risk in vulnerable populations. 6 Using multimodality imaging methods, both structural and functional abnormalities in the heart can be noninvasively monitored. 7 At the same time, morphological and functional changes in the heart representing CVD burden have gained increased importance as clinical endpoints in clinical trials assessing the effect of pharmacological treatments for atherosclerosis. 8 As a result, multimodality cardiovascular imaging has broad application prospects in the management of SLE patients. Cardiovascular imaging biomarkers, which play important roles in monitoring the status of the cardiovascular system, are expected to facilitate clinical decision making by evaluating the cardiovascular benefits and harms of comprehensive SLE treatments.
By describing currently available cardiovascular imaging techniques, we will be focusing on recent cardiovascular imaging advances, including their potential applications and limitations in SLE management. We will also discuss the selection of appropriate imaging methods to measure various cardiovascular indices for different clinical purposes.
Major cardiovascular complications

CAD
Compared to the general population, SLE patients encounter a higher incidence of cardiovascular events. 4 About 13% of SLE patients have symptomatic atherosclerotic lesions, such as angina and myocardial infarction (MI). 9 Additionally, subclinical CAD may be prevalent in asymptomatic SLE patients, especially in young patients. In a retrospective autopsy study, silent atherosclerotic lesions were found in nearly half of SLE patients who died of various causes. 10 Due to absolute low incidence of cardiovascular events in SLE cohorts, noninvasive quantification of subclinical CAD burden is important to evaluate the mid-term efficacy of cardiovascular prevention for SLE patients.
Traditionally, the result of X-ray digital subtraction angiography (DSA) is the ''gold standard'' for the detection of coronary stenosis, an immediate manifestation of MI consequent to CAD. However, DSA is an invasive examination and its application is limited in asymptomatic individuals because of X-ray exposure. In the past decade, coronary computed tomography angiography (CTA) with multidetector computed tomography (CT) (MDCT) has gradually become an accurate method (with high positive and negative predictive values) for screening coronary stenosis. 11, 12 In addition, coronary CTA can also quantify calcification score (CS), a traditional index of CAD burden. Using electron-beam computed tomography (EBCT) to scan 65 SLE patients and 68 controls, Asanuma at al. found that SLE patients had a higher CS compared to controls. 13 Because of its poor spatial resolution, EBCT (with excellent temporal resolution) has been replaced by MDCT in most medical institutions. Compared to healthy volunteers, SLE patients had elevated prevalence and severity of calcification over the cardiovascular system. 14 16 In a study based on positron-emission tomography (PET) with oxygen-15 labelled water, Recio-Mayoral et al. observed reduced coronary flow reserve (CFR), an early predictor of premature CAD, in 25 patients with SLE or rheumatoid arthritis (RA). 17 Recent pathological studies have shown that many acute coronary events were triggered by superficial plaque erosion or rupture of vulnerable plaques without significantly obstructive lesions. 18, 19 Presence of vulnerable coronary plaques is the most reliable predictor of near-term cardiovascular events and serves as an indicator for treatment, such as coronary artery bypass graft surgery (CABG) and percutaneous transluminal coronary angioplasty (PTCA). Therefore, direct detection of vulnerable plaque on the coronary wall is the most straightforward method for CAD diagnosis. However, X-ray angiography shows only the coronary lumen. It is thus difficult for DSA to identify ''vulnerable'' coronary plaque on the coronary wall. Using intravascular ultrasound (IVUS), Schoenhagen et al. found that positive remodeling and larger plaque areas were associated with unstable coronary syndromes in 131 individuals. 20 In a recent clinical trial, the percentage of atheroma volume (PAV), a similar signature of coronary artery remodeling acquired using IVUS, has been adopted as the primary endpoint to assess the efficacies of regimens for the treatment of CAD. 8 In addition, coronary optical coherence tomography (OCT) is a catheter-based imaging system that can be employed to produce high-quality images of the coronary wall and lumen using light instead of ultrasound. 21 Unfortunately, neither IVUS nor OCT can be widely used in asymptomatic patients because of their invasiveness. Recently, magnetic resonance imaging (MRI) has emerged as a radiation-free, non-invasive method for the accurate detection of atherosclerosis. 22, 23 Using IVUS as a reference, He et al. found that MRI could accurately depict plaques in the proximal part of the coronary arteries. 23 Results from our group and those of other researchers have also demonstrated that MRI allows for the repeatable, reproducible and quantitative evaluation of coronary thickness and stiffness in asymptomatic individuals at high risk of CAD. [24] [25] [26] Figure 1 shows a thickened coronary wall in a patient with multiple cardiovascular risk factors. Using contrast-enhanced (CE) MRI, Varma et al. found that diffuse coronary CE, which is generally considered as a manifestation of both inflammation and atherosclerotic plaque stability, was more prevalent in SLE patients (n ¼ 27) as compared to healthy volunteers (n ¼ 23). 27 
Myocarditis
As a manifestation of myocardial inflammation, myocarditis occurs in nearly 10% of SLE patients and serves as a prominent contributor of heart failure (HF) and poor prognosis. 28, 29 Functional and structural abnormalities in the left ventricle (LV) are the most prominent presentations of inflammatory myocardial damages in SLE.
Echocardiography is the standard clinical diagnostic tool for the evaluation of cardiac function and motion, such as LV ejection fraction (LVEF), mass, LV deformation, LV distortion, and ventricular wall movement. Speckle tracking echocardiography (STE) is a cardiac ultrasound technique that allows us to dynamically describe and quantify abnormal myocardial motion. 30 In the past decades, cardiac MRI has gradually become an ''operator-independent'' method for cardiac examination and motion. Cardiac MRI (cine, based on a steady-state free precession (SSFP) technique) has become the gold standard for measuring ventricular volumes, LVEF and mass. Multi-parametric MRI techniques can also be used to detect subtle myocardial changes before significant cardiac function decrease can be identified. T1 value is a key characteristic of the tissue. 31 Native T1 mapping can be used to detect acute myocarditis and myocardial fibrosis. 32 Figure 2 demonstrates the variations of T1 values (in the myocardium and blood-pool) before and after the administration of contrast agents. Late gadolinium contrast enhancement (LGE) is a useful method to detect a silent subclinical ischemic myocardial lesion. 35 O'Neill et al. found that LGE presented in SLE patients with and without CVDs using MRI. 36 37 Mavrogeni et al. reported that MRI (short tau inversion recovery (STIR) T2-weighted images and LGE) can detect infective myocarditis in SLE patients using endomyocardial biopsy (EMB) as the reference. 38 Recently, some fast new MRI techniques have been developed to detect subclinical MI. In a recent preclinical study, Nguyen et al. developed a novel myocardial MRI technique (diffusion-weighted imaging, DWI) to successfully detect ischemia lesions in an animal model. 39 Cardiac MRI can also be used to track ventricular motion (systolic and diastolic) abnormalities consequent to myocardial damage. Generally, abnormal ventricle motion may be secondary to various primary disorders, including myocarditis, cardiomyopathy, macro-and microvascular diseases and HF. In this context, MRI-tagging can be employed to describe cardiac motion and deformation. 40 With regions of reduced signal intensity generated by locally induced perturbations of the magnetization, multiple visible tag grids are created within the tissue as the references in the imaging plane for the calculation of regional myocardial tissue displacements. 41 Using tagging MRI, Larghat et al. detected increased LV mass and LV torsion in asymptomatic patients with type 2 diabetes mellitus (T2DM) at high cardiovascular risks. 42 Cine displacement encoding with stimulated echoes (DENSE) and strain encoding (SENC) are advanced MRI techniques that allow for reliably quantifying cardiac strain and deformation in three-dimensional (3D) space. 43 With the DENSE technique, Ernande et al. demonstrated subclinical systolic myocardial dysfunction (indicated by decreased circumferential (Ecc) and radial (Err) systolic strains) in 37 T2DM patients without overt CVDs. 44 See Figure 3 for the description of myocardial motion using DENSE. Similar to DENSE, tissue phase mapping (TPM) is another promising cardiac motion tracking technique. TPM encodes regional velocity information instead of myocardial displacement directly into phase images. In 58 healthy volunteers, Fo¨ll et al. detected differences on regional myocardial motion (represented by peak velocities in circumferential radial and long-axis directions) between different age and gender groups. 45 Myocardial feature tracking (FT) is a more recently introduced approach for myocardial motion tracking based on traditional cine MRI images to derive ventricular mechanics in various directions. 46 However, the capability of novel techniques for the assessment of SLE-specific myocardial lesions still needs to be further validated under clinical circumstances.
Valvular disease
In SLE patients, active autoimmune reactions increase levels of immune factors in the blood. Circulating immunoglobulin and complement components can concentrate and deposit in the valve (b) Ten minutes after the administration of a single dose of gadopentetate dimeglumine, the average T1 values of myocardium and blood-pool were reversed to 659.4 ms and 495.5 ms, respectively. (c) Twenty minutes after the administration of a single dose of gadopentetate dimeglumine, the average T1 values of myocardium and blood-pool evolved to 737.5 ms and 619.9 ms, respectively. and damage its structure. 47 Varied valve involvement, including valve thickening (fibrosis or calcification), leaflet perforation, stenosis, valve regurgitation and valve mass (Libman-Sacks vegetations) can be found in all valves in the heart. 48 However, the mitral valve is most vulnerable. Valvular involvement may progress over time. In clinical practice, multimodality imaging methods can be used to guide treatment by assessing: 1) morphological abnormalities of the valves, and 2) subsequent valvular dysfunction and its subsequent hemodynamic changes.
Cardiac catheterization is a traditional invasive method to investigate the valve status. In clinical practice, echocardiography, including transthoracic echocardiography (TTE), transesophageal echocardiography (TEE) and live 3D echocardiography (RT3D), are routine, noninvasive approaches to determine the morphological and functional features of the valves. 49, 50 TEE demonstrated that 60-74% of SLE patients experience some kind of valvular disease. 51 Recently, cardiac MRI has become a promising diagnostic test for the evaluation of valves. MRI can assess leaflet thickening, leaflet prolapse or redundancy, leaflet fusion/missing and vegetations. 52 Using black-blood MRI, Arai et al. detected abnormal aortic valves (two leaflets or no leaflets) in seven patients. 53 Morphological changes of the valve, such as the anterior and posterior leaflet length of the mitral valve, can be measured by using MRI. 54 MRI has been proven to accurately quantify insufficiency and regurgitation of aortic and mitral valves compared to TTE or cardiac catheterization as the reference standards. [55] [56] [57] MRI may also detect the existence of hemodynamic abnormalities. Recently, four-dimensional (4D)-flow MRI has been developed to assess hemodynamic changes associated with heart valve diseases. For example, Mahadevia et al. demonstrated the relationships among altered regional wall shear stress, flow patterns, and aortopathy in 75 bicuspid aortic valve (BAV) individuals using 4D-flow MRI. 58 Although ongoing clinical studies in our group and others are aiming at validating those cutting-edge MRI techniques for monitoring valve involvement in SLE patients, echocardiography remains the first choice in clinical practice.
Endocarditis
Both infective and noninfective endocarditis (Libman-Sacks) can occur in SLE patients. Local inflammation activity or injury plays an important role in the etiology of endocarditis. Ultrasound is the standard of care for the diagnosis of endocarditis in SLE patients. 59 In addition, MRI, MDCT and novel molecular imaging methods, such as 18 F-fluorodesoxyglucose ( 18 F-FDG) PET-CT and SPECT/CT (the combination of two imaging facilities), have been used to detect endocarditis. 50 
Arrhythmias
Active inflammation in connective tissue may involve the transduction system in the heart. Arrhythmias, such as sinus tachycardia, atrial ectopic beats and atrial fibrillation, can exist in SLE patients. 2 Although arrhythmias are diagnosed by using electrocardiogram (ECG), their existence can significantly affect the performance of clinical imaging tests. Some imaging methods, such as DSA and ultrasound, are not significantly affected by arrhythmias. However, other imaging methods, including CT and MRI, need to acquire imaging data during appropriate acquisition windows with minimal cardiac motion. Currently, the ECG signal is widely used to identify such time windows and to trigger the image acquisition during multiple cardiac cycles. An irregular ECG signal can cause false triggering and result in inferior image quality for diagnostic use. As a result, patients with arrhythmia are excluded for many MRI and CT examinations in clinical practice. Therefore, the existence of arrhythmias should be considered in the selection of suitable clinical imaging methods. 
Related cardiovascular risk conditions outside the heart
CVDs have inherent connections with other coexisting risk conditions in SLE patients. Multimodality imaging may be used to monitor those comorbidities.
Kidney dysfunction
LN is another prominent cause of SLE-related morbidity and mortality. Impaired kidney function has been considered as an independent contributor of CAD and HF. Traditional imaging methods, such as B-mode ultrasound and X-ray intravenous pyelography (IVU) can assess the morphological and functional changes associated with kidney damage. Recently, a number of MRI techniques have been developed for noninvasive detection of subclinical structural and functional changes in the kidney, including blood oxygen level-dependent (BOLD) and arterial spin labeling (ASL) techniques for the measurement of renal parenchymal hypoxia and fibrosis, 60, 61 DWI for the detection of renal tubulointerstitial alterations, 62 diffusion tensor imaging (DTI) for observation of renal microstructure, 63 magnetic resonance elastography (MRE) for the evaluation of renal tissue stiffness, 64 and magnetic resonance angiography (MRA) and 4D-flow imaging for the assessment of renal vasculature and blood supply. 65, 66 Stroke SLE patients have a high incidence of cerebral-vascular diseases. Atherosclerotic lesions in the blood supply system and thrombosis or shedding vegetations from the heart are major sources of ischemic stroke in SLE. 67 CT and MRI are the standard of care in the diagnostic work-up of stroke. Imaging of the carotid and intracranial arteries with ultrasound or MRI may help predict the risk of stroke. [68] [69] [70] Pulmonary artery hypertension (PAH)
Under SLE-specific circumstances, many pathophysiological mechanisms, including a continuing injury/repair progression of the vessel wall and recurrent thrombosis to interstitial fibrosis, may contribute to the damage of the pulmonary vasculature and result in PAH. 71, 72 The gold standard for the diagnosis of PAH is catheterization. In clinical practice, TTE, MRI and CT are routine, noninvasive examinations for the evaluation of PH and its effects on the heart, such as right ventricle (RV) pressure overload. 73 Peripheral artery disease (PAD)
Generally, noninvasive ultrasonography can be used to evaluate superficial vascular territories. However, atherosclerosis is a disease affecting the entire body. Atherosclerotic burden of peripheral arteries may convey the risk of CAD. PAD patients have a high incidence of CAD and coronary events. 74 Manifestations of atherosclerosis on peripheral arteries are associated with the development of CAD. 75 Using B-mode ultrasound, El-Magadmi et al. showed impaired flow-mediated dilation (FMD, representing endothelial dysfunction) in the brachial artery and increased carotid intima-media thickness (IMT, an indicator of atherosclerosis) in female SLE patients (n ¼ 62). 76 In clinical practice, CTA and MRA are the standard of care for the detection of lumen stenosis in peripheral arteries. 77, 78 Pericarditis Nearly 40% of SLE patients have acute and chronic inflammatory pericardial changes and most of them are asymptomatic individuals. 2 It is usually not considered as a life-threatening complication. However, early diagnosis and immediate treatment can reduce the risk of constrictive pericarditis, a long-term sequela of pericarditis. By quantifying thickened pericardial layers and the volume of effusion, echocardiography is the standard of care for diagnosing pericarditis and monitoring the efficacy of treatments. Other imaging methods, such as chest X-ray, MRI and CT, can also be used to detect pericarditis.
Summary and future directions
The cardiovascular system is vulnerable to SLE. In this review, we have discussed clinical applications and limitations of clinical imaging methods for the screening and diagnosis of various SLE-related cardiovascular abnormalities as summarized in Table 1 . It is obvious that there are interconnected relationships among various cardiovascular disorders. A single indicator may represent multiple cardiovascular complications while a single cardiovascular disorder may have various abnormalities from different aspects. Therefore, the combination of multiple imaging methods will greatly increase the efficacy of current methods in guiding personalized SLE management. Candidates for novel quantitative imaging biomarkers are expected to reflect the Imaging of cardiovascular complications in patients with SLE K Lin et al.
individual responses to two essential arms of comprehensive cardiovascular prevention for SLE patients, general SLE therapy (targeting primary autoimmune disorders) and intentional cardiovascular protection (targeting cardiovascular risk conditions). However, many state-of-the art imaging techniques need to be purposefully validated in the SLE population. The clinical relevance of those potential imaging biomarkers should be evaluated for predicting the cardiovascular outcomes in large SLE cohorts. In addition, the cost effectiveness of novel imaging approaches (or combinations of multiple imaging examinations) for SLE management needs further assessment in future clinical studies.
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